Mercia EIS Fund

Deadline: 28 June 2019

The Mercia EIS fund is an evergreen offer focusing on early-stage technologies from university spinouts and industry. Mercia has an extensive commercial network across the Midlands, North of England and Scotland and makes initially small investments across the regions. Through its parent company Mercia Technologies, it then has the ability to provide later stage support to successful investments, offering what it calls a “complete capital solution”.


  • EIS offer with an SEIS option
  • Seeks to commercialise high-growth technology and intellectual property from industry and university spin-outs
  • Target return 3x including tax relief (returns not guaranteed)
  • Particular focus on the Midlands, North of England and Scotland
  • Experienced, well-resourced team
  • Portfolio expected to consist of around 15 companies with advance assurance
  • Additional exit route and early liquidity potentially offered by AIM-listed Mercia Technologies
  • Minimum investment £25,000

Important: The information on this website is for experienced investors. It is not advice nor a research or personal recommendation to invest. If you’re unsure, please seek advice. Investments are for the long term. They are high risk and illiquid and can fall as well as rise in value, so you could get back less than you invest.

Read important documents and apply

The manager

Mercia Fund Management Ltd is an early stage technology investor managing EIS funds and government money to develop and commercialise technology from industry and universities. It was founded in 2000 to manage money for the West Midlands Enterprise Fund and was originally named WM Enterprises Ltd.

Dr Mark Payton, CEO, led Mercia’s buyout from West Midlands Enterprise in 2010. This opened the door to external investors and Mercia’s first EIS fund.

Mercia Fund Management is part of Mercia Technologies Plc which also owns Enterprise Ventures. 

Mercia Technology Plc listed on AIM in 2014 and has over £500 million assets under management. Its largest shareholders include Invesco Perpetual, Woodford Investment Management, Forward Innovation Fund and Baillie Gifford.

By funding early-stage businesses via multiple funding rounds which gradually increase, Mercia aims to weed out failures and provide later stage support for successful companies through to possible exit. Mercia’s EIS and third-party funds provide support at the earlier stages and pass the reins to Mercia Technologies Plc to support businesses at the scale up stage. If larger amounts are required the Plc’s shareholders (such as Woodford and Invesco) may also be invited to participate. This offers the potential for early liquidity as well as a possible additional exit route for investors, although as always exit options are not guaranteed.

Mercia invests nationwide but has a particularly strong presence in the Midlands, the North of England and Scotland. It has partnership agreements with 19 UK universities.

Watch an exclusive video interview with Paul Mattick and Julian Dennard of Mercia Fund Management:

The offer

The default investment will be entirely EIS, but there is an option to invest in SEIS qualifying companies. Indeed, the same company may receive SEIS funding in one round, and EIS funding later. However, there will be distinct differences. Mercia will usually take a greater stake in the business in any SEIS round, as it will likely be diluted later. In addition, the technology or intellectual property will probably be further away from commercialisation. 

Unless otherwise specified, 100% of an investor’s subscription will be invested in EIS-qualifying companies, but there is an option to invest up to 15% of an investor’s subscription in SEIS-qualifying companies. The SEIS fund is limited to £600,000 and will be allocated on a first-come first-served basis at Mercia’s discretion.

The minimum investment is £25,000. The portfolio is expected to consist of around 15 companies with EIS advance assurance.

Investment strategy

The Mercia EIS Fund will invest in early-stage technology businesses with the aim of generating capital growth. It will invest in four key sectors where technology or intellectual property can be patented and exploited:

  • Life sciences and biosciences (particularly diagnostics, digital health and medical devices)
  • Digital and digital entertainment (such as virtual reality games, or mixed reality games)
  • Software and internet (cyber security, SaaS or artificial intelligence)
  • Electronics, materials, manufacturing & engineering

A proportion of these deals will come from Mercia’s extensive commercial networks, which include the investment directors’ personal networks as well as regional incubator programmes and the NHS Feeder Fund.

Others will be spin-outs from universities. Currently there are 19 university partnerships including Edinburgh, Birmingham, Liverpool and Warwick.

Universities and their dedicated research teams are responsible for many of the current pioneering breakthroughs in science and technology across the globe. It is often the ‘Golden Triangle’ of Oxford, Cambridge and London that grabs investor attention, but Mercia believes there is opportunity waiting to be tapped in the UK regions. According to Mercia, 52% of all active spin-outs in the UK originate from the Midlands, the North of England and Scotland.

Mercia’s university team, headed by Dr Nicola Broughton, works closely with the Technology Transfer Departments of each of the 19 university partners to help support research ideas from laboratory to the market.

Mercia’s growth funds each have their own Investment Panel and external Advisory Committee. For all investments made, the investment team reviews each proposal and circulates the findings to the team for challenge. If the deal passes this stage, a more formal offer is made and detailed due diligence is carried out on the intellectual property. A longer and more detailed review is completed and sent to Mercia’s investment committee. Its members have the power to veto any deal, and have done so in the past. 

Target return

The target return is 3x, however this includes initial tax relief, therefore the effective target (before income tax relief) is to deliver in excess of 2.5 times invested capital. This is not guaranteed. Companies are expected to be held for five to seven years but this may vary.

Exit strategy

As well as the two usual exit mechanisms for EIS investments – stock market listing or trade sale – Mercia has a third option for successful holdings, which could provide potential early liquidity for investors. This is Mercia’s Share Exchange. It means Mercia Technologies may offer to buy shares it itself holds which are also held by investors in the Mercia EIS Fund (including SEIS) at a 25% discount. If offered, investors do not have to take it up if they feel the discount does not offer value for money.

Portfolio companies

Mercia EIS Fund - MedherantAn example of a successful investment: Medherant

Medherant is a spin out from the University of Warwick. It is developing a novel patch technology for the delivery of a variety of drugs.

The TEPI-patch® is a thin, strong, easy-to-apply and easy-to-remove patch capable of delivering high doses of drugs directly to the areas where they are needed.

It has allowed the firm to produce and patent the world’s first ever ibuprofen patch. This can consistently deliver a prolonged high dose of the painkiller ibuprofen directly through the skin via a polymer matrix that sticks the patch to the patient’s skin. The drug is then delivered at a steady rate over up to 12 hours. This opens the way for the development of a range of novel long-acting over-the-counter pain relief products which can be used to treat common painful conditions like chronic back pain, neuralgia and arthritis without the need to take potentially damaging doses of the drug orally. Although there are a number of popular ibuprofen gels available these make it difficult to control dosage and are inconvenient to apply.

This novel patch incorporates polymer technology developed by the global adhesive company Bostik and exclusively licensed for transdermal use to Medherant. 

The technology is also capable of working with drugs that have failed clinical trials because of their unsuitability for oral consumption. 

Mercia invested £398,551 from the EIS funds in Medherant and follow on investment has been provided by Mercia Technologies. 

Note that this is an example of an existing holding only; the latest tranche of the Mercia EIS Fund will hold different companies. 

An example of a failed investment: DMPortal

There have been a number of failures in previous Mercia EIS Funds, as is to be expected. 

All but four received only SEIS investment. One example is DMPortal which received £150,000 investment from Mercia Growth Fund 1 (SEIS) and Mercia Growth Fund 2 (SEIS) in 2014. The company provided a SaaS (Software as a Service) platform for vehicle dealerships and transporters by offering an online logistics and auction solution.

The online portal was set up to rival traditional auction houses, where dealers could sell used and ex-lease vehicles without the need for physical transportation. DMPortal also hosted a car movement module, providing an opportunity for transporters to gain business and reach full capacity for inbound and outbound journeys, whilst offering an efficient alternative for dealerships delivering and collecting vehicles.

The company showed promise but the founder was not able to deliver early revenue or reach commercial targets. The company underwent an orderly liquidation on 9 June 2015 and the investment was written off. 


Source: Mercia Fund Management. EIS funds only. Returns calculated using Mercia's own valuations. Figures exclude the benefit of tax relief. Past performance is not a guide to the future.

Annual Performance to September 2018

  September 2014 September 2015 September 2016 September 2017 September 2018
MGF1 6.8% 70.9% 0.2% -4.6% 7.5%
MGF2 0.0% 42.7% 51.5% 20.0% 5.6%
MGF3 67.3% 5.7% -14.4% -26.5%
MDF 30.1% 35.9% 24.1% -9.9%
MGF4 4.4% -16.7% 11.3%
UGF 14.8% -7.4% 12.9%
MGF5 -11.3% -1.2%
MGF6 -9.5% -5.8%

Source: Mercia Fund Management. Shows annual % growth in Mercia Growth Funds since April 2013. Returns calculated using Mercia's own valuations. EIS funds only. Figures exclude the benefit of tax relief. Past performance is not a guide to the future.

Risks – important

This, like all investments available through Wealth Club, is only for experienced investors happy to make their own investment decisions without advice.

EIS / SEIS investments are high-risk so should only form part of a balanced portfolio and you should not invest money you cannot afford to lose. They also tend to be illiquid and hard to sell and value. Before you invest, please carefully read the Risks and Commitments and the offer documents to ensure you fully understand the risks. 

Tax rules can change and benefits depend on circumstances.

This EIS / SEIS fund invests in early-stage businesses which are more likely to fail than larger ones. So you should expect a number of failures in the portfolio.

Mercia’s investment remit is not confined to EIS investments. This can have advantages but also means there could be scenarios where Mercia’s non-EIS investments take priority over the EIS funds, for example regional deals supported by Government-backed development funds.

Fees and charges

A summary of the fees and charges is shown below. Please see the provider's documents for more details.

Full Initial charge 2%
Saving through Wealth Club 0%
Net initial charge 2%
Annual custodian fee 0.25%
Transaction fee 0.35%
Performance fee 20%

More detail on the charges

Our view

Investing in start-up and spin-out technologies is an exciting area for wealthy investors. It is high growth but also high risk. This portfolio is one way of tapping into this market with generous EIS (and SEIS) tax benefits. Mercia has invested in spin-outs and technology commercialisation for many years so has undoubted experience in this sector. Its regional presence provides good deal flow as well as access to quality deals which managers based in London or the South East may miss. 

Early-stage businesses often need more than one round of funding to achieve profitability and exit. Unlike some other EIS managers, Mercia has the ability to make multiple rounds of funding using SEIS and EIS for the early rounds followed by Mercia Technologies’ own balance sheet for the later ones. This Mercia “complete capital solution” offers potential early liquidity at a discount, which could prove attractive to some.

Read important documents and apply

Wealth Club aims to make it easier for experienced investors to find information on – and apply for – tax-efficient investments. You should base your investment decision on the provider's documents and ensure you have read and fully understand them before investing. This review is a marketing communication. It is not advice or a personal or research recommendation to buy the investment mentioned. It does not satisfy legal requirements promoting investment research independence and is thus not subject to prohibitions on dealing ahead of its dissemination.

The details

Technology & life sciences
Target return
Funds raised / sought
£9.4 million / £30.0 million
Minimum investment
28 Jun 2019 for next allotment
Last updated: 30 January 2019

News about Enterprise Investment Scheme. Read all